Alpha Tau Medical (NASDAQ:DRTS) presented early clinical results from the first three patients treated in its REGAIN study of Alpha DaRT for recurrent glioblastoma, with company executives and clinical investigators describing initial tumor responses and safety observations from the pilot trial.
The event was led by Raphi Levy, Alpha Tau’s chief financial officer, who was joined by founder and Chief Executive Officer Uzi Sofer, Chief Medical Officer Dr. Robert Den and Dr. Joshua Palmer, professor of radiation oncology and vice chair of advanced imaging and experimental therapeutics at The Ohio State University Comprehensive Cancer Center.
